Acurx Pharmaceuticals, Inc. - Common Stock (ACXP)

STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQACXP), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 28 to January 30, 2025 at the Borgata Hotel, Atlantic City, New Jersey.

The episode, airing at 9:30 PM PST, will include insights from The Sustainable Green Team with CEO Tony Raynor and Jimmy Houston.

Also appearing on the show are, Sustainable Green Team (OTCQX:SGTM), Andie Monet with David Fagen, and SEKUR (OTCQX:SWISF)

New to The Street, the premier platform for introducing cutting-edge companies, is excited about Bloomberg TV's interviews which aired on Saturday, October 12, 2024 featured key industry leaders , sponsored by PetVivo Holdings Inc. (PETV), including: Zapp Electric Vehicles Group Limited (NASDAQZAPP), NUBURU (NYSEAM: BURU), Acurx Pharmaceuticals, Inc. NASDAQ: ACXPNASDAQACXP)

The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign.

Featuring ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week

Acurx Pharmaceuticals, Inc. (NASDAQACXP) is one of today’s top gainers. The company’s shares are currently up 42.08% on the day to $2.73.

Featuring ZAPP, NUBURU, ACURX Pharmaceuticals, The Sustainable Green Team, and SEKUR's Hack of the Week

Opportunities To Consider™

The New to the Street TV series interviews are broadcast nationally on Bloomberg and Fox Business News, targeting investors. These segments offer a glimpse into companies spotlighted or soon to be featured on these networks.

Acurx Pharmaceuticals, Inc. (NASDAQACXP) stock may present an investment opportunity that is too good to ignore. That assessment is more than warranted; it's justified, based on results from its Phase 2b clinical trial of its lead antibiotic candidate, ibezapolstat, for treating patients with Clostridioides difficile Infection ( C. difficile, CDI). The data is more than compelling; it puts the target ACXP aims for, front-line treatment designation, in its crosshairs. And plenty supports hitting the bullseye.

Acurx Pharmaceuticals, Inc. (NASDAQACXP) stock is getting massive interest. Of course, the question is- why? Speculation is that its related to ACXP nearing a data release for its Phase 2b clinical trial targeting treatment for C. difficile, one of the most common causes of healthcare-associated infections in U.S. hospitals that is estimated to affect over 450,000 patients annually and, worse, is associated with approximately 20,000 deaths annually. That's just in the U.S. Using a global measure, that number gets a significant multiple.

Acurx Pharmaceuticals' (NASDAQACXP) earnings release is scheduled for Thursday, March 16, 2023. And like most biotechs, investors will be more focused on what the company says than what it posts. That's typical. Clinical-stage drug development companies rarely post meaningful revenues. But, they provide guidance and clinical program updates, two areas where investors can appraise what the company is doing and where it's going. Acurx Pharmaceuticals is expected to present plenty of each, and they could be milestones reached.

There's good news, and then there's excellent news. The good news is that Acurx Pharmaceuticals (NASDAQACXP) is nearing its Phase 3 trial to get a best-in-class front-line treatment for C. difficile to the market. The excellent news is that millions of patients could potentially be cured of this debilitating condition with vastly reduced recurrent infection saving billions in downstream costs to the healthcare system.

Acurx Pharmaceuticals' (NASDAQACXP) mission in bringing to market an effective and durable treatment for C. difficile was provided a significant step forward. This time, it came as a result of yet another Phase 3 topline miss, with the late-stage clinical trial competitor Finch Therapeutics NASDAQ: FNCHNASDAQFNCH)

C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United States and it causes approximately 55 deaths a day. In the elderly population, 1 in 11 individuals over the age of 65 die within the month after being infected. The infection has a high recurrent rate, about 1 in 6 patients who get C. diff will get it again within 2-8 weeks.

Acurx Pharmaceuticals (NASDAQACXP) stock has broken through a consolidation phase at the $3.57 level, surging by more than 29% in August. Exchanging hands at roughly $4.60 on Tuesday, the bullish momentum could put all-time highs of $5.92 made during 2021 back in the near-term crosshairs. A recent spike in volume, riding a wave of excellent interim Phase 2 trial data, possible grant awards, and potential partnerships could make that happen sooner than later.

Finding an effective treatment against C. difficile has been challenging, with the past few decades serving up little more than short-term relief from CDI's debilitating symptoms. But, one micro-cap company, Acurx Pharmaceuticals (NASDAQACXP), is on the right path to changing the treatment landscape with its CDI treatment drug candidate showing best-in-class front-line treatment potential.

Acurx Pharmaceuticals (NASDAQACXP) remains one of the most promising under-the-radar companies in biotech. In fact, current ACXP share prices don't touch the surface of the revenue-generating opportunity at hand. In play is Acurx Pharmaceuticals potentially bringing to market a treatment drug that could capture the front-line position to treat one of the most debilitating infections known- C. difficile infection (CDI). And the better news, aside from patients finally getting effective treatment, is that ACXP appears to be the most promising drug candidate that remains in the running to lay claim to front-line therapy in the $1.6 billion CDI market. The rewards of doing so could be tremendous.

Acurx Pharmaceuticals' (NASDAQ: ACXP, $ACXP) is stalking its opportunity to become the front-line CDI treatment against C. difficile (CDI). In fact, after Pfizer (NYSEPFE) reported missing its trial primary endpoint in its CLOVER Phase 3 trial targeting treatment for C. difficile, ACXP'sopportunity to bring a best-in-class CDI drug to market has never looked better. Moreover, from the looks of things, ACXP's trial may present one of the last chances to get an effective CDI treatment to market anytime soon.

Acurx Pharmaceuticals' (NASDAQACXP ) competitive position in the race to bring an effective treatment against C. difficile (CDI) just got stronger. That's because another Big Pharma player, Pfizer NYSE: PFENYSEPFE )(NYSE: SNYNYSESNY and Summit Therapeutics (NYSE: SMMTNYSE), which also posted disappointing topline results in their missions to tap into themore than $1.5 billion CDI treatment market. But, for ACXP, the misfortune of others can lead to a windfall of opportunities and more importantly, positions them as one of the few, if only, known clinical stage companies without a blemish on its trial record to treat the debilitating infection. Thus, the recent beat down in small-cap biotech, ACXP included, has created more than an attractive investment proposition; it exposed a compelling one.

Following a period of bearish conditions, investors are anxiously awaiting the next big rally. A return to normal levels would help revitalize investor portfolios and confidence following a difficult month for the markets. However, the return to bullish conditions may come sooner than many may believe –especially for those companies that navigated the situation wisely. Acurx Pharmaceuticals, Inc. (NASDAQACXP) is one of those companies that have consistently pushed through its clinical trials and are beginning to post the results that could send them back to all time highs. And, with ACXP closing out 2021 as a year filled with some of its most significant developments yet, a rally may very well be within reach.

Abbreviated trading weeks have a way of keeping potentially transformative news under the radar. And it's happened again. This time, investors are overlooking just how important Summit Therapeutics (NASDAQSMMT) topline miss in its Phase 3 trial to treat C. difficile can be for Acurx Pharmaceuticals NASDAQ: ACXPNASDAQACXP )

Investors have something high on their wish list- a Santa Claus rally. Indeed, it would be timely and, more importantly, help salvage some portfolio value after a brutal month of selling. The good news...Santa does have a way of showing up at the right times. Better still, if history is a guide, his holiday magic has a way to send the "nice" stocks on his list considerably higher. Acurx Pharmaceuticals, Inc. (NASDAQACXP) is definitely high on the page. And with what has been nothing short of a transformational growth period for Acurx in 2021, joining a Santa Claus rally will be well-deserved.

Acurx Pharmaceuticals, Inc. (NASDAQACXP) may be one of, if not the, most undervalued small-cap biotech stocks in the market. Sure, that's a bold assessment, but considering what ACXP is doing and how far along they are in that process, it's one that's justified. In fact, this year has been so transformative to the growth of ACXP that the value proposition is simply too big to ignore.